Zhou Li-Li, Shen Yong, Gong Jiao-Mei, Sun Ping, Sheng Jia-He
Department of Clinical Laboratory, Affiliated Cancer Hospital of Zhengzhou University & Henan Cancer Hospital, Zhengzhou, Henan, China.
Department of Clinical Laboratory, Second Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan, China.
Oncotarget. 2017 Aug 7;8(41):70821-70827. doi: 10.18632/oncotarget.19992. eCollection 2017 Sep 19.
Cervical cancer is the second most common cancer in women in the world. In this study, we explore tumor markers and microRNA-466 combination for cervical cancer screening. Tumor markers were measured by the methods of electro-chemiluminescent immunoassay and enzyme immunoassay. The microRNA-466 was performed by quantitative real-time polymerase chain reaction. Among normal group, hyperplasia group and cancer group, the CEA expression levels were 2.26 ng/ml, 3.85 ng/ml and 16.08 ng/ml, respectively. While the CA125 expression levels were 13.61 u/ml, 27.32 u/ml and 44.93 u/ml, respectively. The SCCA expression levels were 13.61 ng/ml, 27.32 ng/ml and 44.93 ng/ml, respectively. The expression levels of tumor markers were all gradually increased with the development of cervical lesions. The expression levels of microRNA-466 in cervical cancers (0.62) were greater than that in normal (0.076) and hyperplasia (0.24). The expression of microRNA-466 was correlated with lymphnode metastasis (=0.000). There is a lower overall survival rate of patient with large tumor or lymphnode metastasis. Thus, the combination of tumor markers and microRNA-466 can be useful for early detection of cervical cancer and indicators for advanced stage and prognosis of the disease.
宫颈癌是全球女性中第二常见的癌症。在本研究中，我们探索肿瘤标志物与微小RNA-466联合用于宫颈癌筛查。肿瘤标志物采用电化学发光免疫分析法和酶免疫分析法进行检测。微小RNA-466通过定量实时聚合酶链反应进行检测。在正常组、增生组和癌症组中，癌胚抗原（CEA）表达水平分别为2.26 ng/ml、3.85 ng/ml和16.08 ng/ml。而糖类抗原125（CA125）表达水平分别为13.61 u/ml、27.32 u/ml和44.93 u/ml。鳞状细胞癌抗原（SCCA）表达水平分别为13.61 ng/ml、27.32 ng/ml和44.93 ng/ml。肿瘤标志物的表达水平均随着宫颈病变的发展而逐渐升高。宫颈癌中微小RNA-466的表达水平（0.62）高于正常组（0.076）和增生组（0.24）。微小RNA-466的表达与淋巴结转移相关（=0.000）。肿瘤较大或有淋巴结转移的患者总生存率较低。因此，肿瘤标志物与微小RNA-466联合可用于宫颈癌的早期检测以及疾病晚期和预后的指标。
